Jeffrey S. Humphrey

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 621 citations · Full text

Cutaneous T-cell Lymphoma, Lymphoid Neoplasia, Medicine +6

Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene

Catherine A. Stolle, G.M. Glenn, Berton Zbar et al. · Human Mutation · 1998 · 476 citations

Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia

Thomas O. Carpenter, Erik A. Imel, Mary D. Ruppe et al. · Journal of Clinical Investigation · 2014 · 311 citations · Full text

Localization of TGN38 to the trans-Golgi network: involvement of a cytoplasmic tyrosine-containing sequence.

Jeffrey S. Humphrey, Peter J. Peters, Lydia C. Yuan et al. · The Journal of Cell Biology · 1993 · 261 citations · Full text

Immunocytochemical Technique, Molecular Biology, Antigen Processing +20

Phase I Clinical Trial Design in Cancer Drug Development

Elizabeth A. Eisenhauer, Peter J. O’Dwyer, Michaele C. Christian et al. · Journal of Clinical Oncology · 2000 · 235 citations

Medicine, Pharmacology, Clinical Trials +13